IDDSI Nutritional Drink for Dysphagia Study

An Evaluation of the Tolerance, Compliance, Acceptability and Safety of a New Oral Nutritional Supplement in Dysphagic Patients

This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.

Study Overview

• Status: Suspended
• Conditions: Malnutrition; Dysphagia
• Intervention / Treatment: Dietary supplement: IDDSI nutritional supplement drink

Detailed Description

Dysphagia is a complex condition common in a number of diagnoses including stroke, Parkinson's disease, head and neck cancer, dementia, learning disabilities and gastric/oesophageal motility disorders.

A modified textured diet and/or fluid is considered as an effective intervention in management of dysphagia. The International Dysphagia Diet Standardisation Initiative (IDDSI) have developed a new framework around the terms and descriptors used in the management of individuals with dysphagia. Malnutrition is very common in patients with dysphagia and the use of pre-thickened oral nutritional supplements (ONS) has been found as an effective way to manage this. However, due to impairment in the swallow process, dysphagic patients require pre-thickened oral nutritional supplement to ensure safe consumption of these nutritional supplements.

40 participants, requiring a new pre-thickened oral nutritional supplement in line with the new IDDSI framework recruited from hospitals, outpatients clinics, care homes, community hospitals, community dietetic/speech and language therapy services or stroke rehabilitation units will receive the ready-to-use oral nutritional supplement for a 4 week intervention period. This study aims to primarily evaluate gastro-intestinal tolerance, with secondary outcomes including compliance, acceptability, nutrient intake, anthropometry and safety.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Caerleon, United Kingdom, NP16 3XQ
    • Aneurin Bevan University Health Board
  • Cambridge, United Kingdom
    • Cambridge University Hospitals NHS Foundation Trust
  • Dudley, United Kingdom
    • Dudley Group NHS Trust
  • Llwynypia, United Kingdom
    • Cwm Taf University Health Board
  • London, United Kingdom
    • Croydon Health NHS Trust
  • London, United Kingdom
    • Lewisham and Greenwich NHS Foundation Trust
  • Swindon, United Kingdom
    • Great Western Hospitals NHS Foundation Trust
  • Weston-super-Mare, United Kingdom
    • Weston Area Health Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female
• Age ≥ 18 years
• Patients with a requirement for ≥ 250kcal/day from a milkshake style ONS for ≥ 4 weeks or current users of ONS
• Patients identified to require mildly thick (IDDSI level 2) fluids.
• Patients competent to provide written informed consent and able to answer questions
• Patients able to take study ONS orally

Exclusion Criteria:

• Patients that lack capacity to provide informed consent
• Patients that are unable to take study ONS orally
• Participants with chronic renal disease requiring dialysis
• Participants with liver failure
• Participants that are pregnant or lactating
• Participation in other studies that may interfere with this study
• Participants receiving 100% total nutritional requirements from tube feeding or parenteral nutrition
• Patients with galactosaemia or lactose intolerance
• Patients receiving palliative or end of life care

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IDDSI nutritional supplement drink; Single arm designed, 28day on IDDSI nutritional supplement drink	Dietary supplement: IDDSI nutritional supplement drink; ready-to-use nutritional supplement drink to be taken daily for 28 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gastrointestinal Tolerance	Gastro-intestinal tolerance will be assessed daily throughout a 3 day baseline period before starting the study ONS and at the end of each week (day 10, day 17, day 24, day 31) using a standardised GI tolerance questionnaire including questions on number of bowel movements per day, other gastrointestinal symptoms such as flatulence, bloating, burping and abdominal discomfort. Patient-reported gastrointestinal symptoms with scale range for each symptom as s scale range minimum = none, maximum = severe. Change of symptom from baseline scale minimum = no change, maximum = worse.	Day 1, Day 2, Day 3, Day 10, Day 17, Day 24 and Day 31

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compliance	Daily questionnaire on amount of nutritional drink prescribed and amounts actually consumed. Amount of daily ONS actually consumed scale minimum = 0%, maximum = 100%	Once during baseline period (Day 1) and then daily through intervention period (Days 4-31)
Acceptability: Brief tick-box questionnaire	Brief tick-box questionnaire on overall liking and acceptability of product, including texture and feel of nutritional drink, flavor and ease of use. Scale minimum = dislike very much, maximum = like very much Scale minimum = very inconvenient, maximum = very convenient Scale minimum = very difficult, maximum = very easy	Day 1, Day 17, Day 31
Anthropometry	Measurements of height and weight with Body Mass Index (BMI) calculated at baseline and end of study.	Day 1 and Day 31
Nutrient intake	Three dietary recalls relating to the the past 24 hours of Day 1, Day 17 and Day 31 to capture all food and fluids consumed. This will subsequently be analysed in dietary software.	Day 1, Day 17 and Day 31
Safety (Adverse events reporting)	Reporting of any adverse events that occur throughout study.	31 days.

Collaborators and Investigators

• Sponsor: Nutricia UK Ltd
• Investigators: Study Director: Rebecca Stratton, Dr, Nutricia Ltd UK

Study record dates

Study Major Dates

• Study Start (Actual): August 28, 2018
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: August 29, 2018
• First Submitted That Met QC Criteria: September 18, 2018
• First Posted (Actual): September 20, 2018

Study Record Updates

• Last Update Posted (Actual): April 14, 2026
• Last Update Submitted That Met QC Criteria: April 9, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Digestive System Diseases; Gastrointestinal Diseases; Esophageal Diseases; Otorhinolaryngologic Diseases; Pharyngeal Diseases; Nutritional and Metabolic Diseases; Malnutrition; Deglutition Disorders
• Other Study ID Numbers: IDDSIL2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No